431 Studies Now Enrolling
Synaptic Therapy Alzheimers Research Trial (START): A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimers Disease over 18 Months
Synaptic Therapy Alzheimers Research Trial (START)
| Sponsor: | National Institute on Aging |
| Enrolling: | Male and Female Patients |
| Study Length: | 72 Weeks |
| IRB Number: | AAAV1618 |
| U.S. Govt. ID: | NCT05531656 |
| Contact: | Brittney Paniagua: (212)305-7661 / brp2127@cumc.columbia.edu |
Additional Study Information:
We are seeking men and women, ages 50-85 years, who have mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease dementia for an 18-month treatment, multi-center, randomized, double-blind, placebo-controlled, parallel-group study to determine whether the CT1812 study drug beneficially affects cognition and function in participants. The study participant will receive MRI and PET scans, and will take an orally administered drug (or placebo) daily.
Do You Qualify?
| Are you 50 to 85 years old? | Yes | No |
| Do you have memory concerns noticed by another person for 6 or more months? | Yes | No |
| Are you or your family member fluent in English or Spanish? | Yes | No |
| Are you able and willing to take the study drug (or placebo) daily in the form of oral capsules? | Yes | No |